Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W B Hillegass

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Pharmacoeconomics|March 17, 2001
Glycoprotein IIb/IIIa receptor therapy in percutaneous coronary intervention and non-ST-segment elevation acute coronary syndromes. Estimating the economic implicationsW B Hillegass, A R Newman, D L Raco
American Heart Journal|July 1, 1999
Economic issues in glycoprotein IIb/IIIa receptor therapyW B Hillegass, A R Newman, D L Raco
American Heart Journal|April 16, 1998
Abciximab therapy in percutaneous intervention: economic issues in the United StatesA K Goklaney, J D Murphy, W B Hillegass
European Heart Journal|May 23, 1998
Abciximab therapy in percutaneous intervention: economic issues in the United StatesA K Goklaney, J D Murphy, W B Hillegass
Catheterization and Cardiovascular Diagnosis|February 24, 1998
Stent procedure complicated by thrombus formation distal to the lesion within a muscle bridgeM Agirbasli, W B Hillegass, G D Chapman, et al.
The American Journal of Cardiology|May 1, 1994
A meta-analysis of randomized trials of calcium antagonists to reduce restenosis after coronary angioplastyW B Hillegass, E M Ohman, J D Leimberger, et al.
The American Journal of Cardiology|June 20, 1996
Use of calcium channel antagonists in myocardial revascularization proceduresR M Califf, B E Tardiff, K S Pieper, et al.
Journal of the American College of Cardiology|April 13, 2001
Treatment of no-reflow and impaired flow with the nitric oxide donor nitroprusside following percutaneous coronary interventions: initial human clinical experienceW B Hillegass, N A Dean, L Liao, et al.
The American Journal of Cardiology|March 1, 1994
Intracranial hemorrhage risk and new thrombolytic therapies in acute myocardial infarctionW B Hillegass, J G Jollis, C B Granger, et al.
European Heart Journal|May 23, 1998
Safe use of platelet GP IIb/IIIa inhibitorsJ J Ferguson, D J Kereiakes, A A Adgey, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Pharmacoeconomics|March 17, 2001
Glycoprotein IIb/IIIa receptor therapy in percutaneous coronary intervention and non-ST-segment elevation acute coronary syndromes. Estimating the economic implicationsW B Hillegass, A R Newman, D L Raco
American Heart Journal|July 1, 1999
Economic issues in glycoprotein IIb/IIIa receptor therapyW B Hillegass, A R Newman, D L Raco
American Heart Journal|April 16, 1998
Abciximab therapy in percutaneous intervention: economic issues in the United StatesA K Goklaney, J D Murphy, W B Hillegass
European Heart Journal|May 23, 1998
Abciximab therapy in percutaneous intervention: economic issues in the United StatesA K Goklaney, J D Murphy, W B Hillegass
Catheterization and Cardiovascular Diagnosis|February 24, 1998
Stent procedure complicated by thrombus formation distal to the lesion within a muscle bridgeM Agirbasli, W B Hillegass, G D Chapman, et al.
The American Journal of Cardiology|May 1, 1994
A meta-analysis of randomized trials of calcium antagonists to reduce restenosis after coronary angioplastyW B Hillegass, E M Ohman, J D Leimberger, et al.
The American Journal of Cardiology|June 20, 1996
Use of calcium channel antagonists in myocardial revascularization proceduresR M Califf, B E Tardiff, K S Pieper, et al.
Journal of the American College of Cardiology|April 13, 2001
Treatment of no-reflow and impaired flow with the nitric oxide donor nitroprusside following percutaneous coronary interventions: initial human clinical experienceW B Hillegass, N A Dean, L Liao, et al.
The American Journal of Cardiology|March 1, 1994
Intracranial hemorrhage risk and new thrombolytic therapies in acute myocardial infarctionW B Hillegass, J G Jollis, C B Granger, et al.
European Heart Journal|May 23, 1998
Safe use of platelet GP IIb/IIIa inhibitorsJ J Ferguson, D J Kereiakes, A A Adgey, et al.
Pageof 2